Study of SHR-A1811 for recurrent ovarian cancer after platinum therapy
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests an investigational medicine called SHR-A1811 for ovarian cancer that has come back after platinum-based chemotherapy. It targets a protein called HER2 on cancer cells to try to stop their growth. This trial is for people who have already tried a PARP inhibitor and have certain genetic features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman between 18 and 75 years old.
- You must have epithelial ovarian, fallopian tube, or primary peritoneal cancer (but not mucinous type).
- Your cancer must have come back or grown at least 6 months after your last platinum-based chemotherapy (like carboplatin or cisplatin).
- You must have a BRCA gene mutation or be HRD positive, and you must have already taken a PARP inhibitor (like olaparib or niraparib).
- You must be able to provide a sample of your tumor for testing (old or new), and the test result does not affect whether you can join.
- You must have at least one measurable tumor (seen on a CT scan) and be in generally good health (able to do daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial is testing a new drug (SHR-A1811) versus standard chemotherapy for women with platinum-resistant ovarian cancer. The study looks at a specific protein (HER2) to see if the new treatment can help slow or stop the cancer.
This trial tests a new drug called SHR-A1811 for ovarian cancer. It may help people whose cancer can be measured on scans and who are still well enough to do daily activities.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests a new drug combination (trastuzumab rezetecan plus carboplatin) with or without bevacizumab, compared to standard chemotherapy, for ovarian cancer that has come back after platinum-based treatment. It aims to see if this combination works better than the usual options.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.